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1 Introduction  
 
US biologic pharmaceuticals are currently the most expensive medicines on the market.  Biologic 
products are complex protein, vaccines, or living entities (e.g. cells) derived from living cell recombinant 
DNA technology or natural sources such as human tissue.  Manufacturing biologics typically requires 
rigorous processes to reduce variability and maintain the structural integrity of the compound (US Food 
and Drug Administration, 2016) Because of the strong association between compound structure and 
therapeutic function, small structural changes in chemical moiety can directly affect and clinical 
properties of the final product. The U.S. biosimilar market is comprised of large molecule biologic 
compounds approved as “generic” versions of approved large molecule biologic medications. Similar to 
generic small molecule products, biosimilars are intended to reduce health care cost by creating 
competition in the biologic marketplace through offering lower priced alternative products.  The 
potential direct savings on biologic spending in the U.S. has been estimated at 44.2 billion from 2014 
through 2024 (Singh, 2015).  Unlike small molecule drugs that face generic competition following patent 
expiration, biologic (large molecule) medicines lack any price competition, thus higher prices extend 
long after patent exclusivity protection.   
The first biosimilar approval pathway to provide lower cost alternatives to biologics was developed by 
European Union (EU) regulators, the European Medicines Agency (EMA) in 2004. In addition to providing 
alternative biologic medication at a reduced cost, biosimilars have been implemented into medical society 
guideline recommendations, thus influencing new standards of medical practice.  An early example of 
biosimilar guideline updates includes the European Organization for Research and Treatment of Cancer 
(EORTC) consortium recommendation to include the biosimilar filgrastim, a colony stimulator factor used 
to reduce the chemotherapy-induced febrile neutropenia associated with cancer treatment in 2010.  
Filgrastim was incorporated as first-line cancer treatment within both EORTC guidelines and National 
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Institute for Health and Care Excellence (NICE) recommendations.  This action was in response to 
improved cost-effectiveness of the biologic originator product filgrastim (G-CSF) Subsequent to biosimilar 
guideline inclusion, filgrastim Drug utilization increased by 104% from January 2009 to January 2014, 
thereby enabling more patients to access treatment at earlier stages within chemotherapy cycles.   
Statutory regulation of biosimilars within the U.S. followed EU biosimilar regulation, enacted as part of 
the Patient Protection and Affordable Care Act (ACA) in 2010 (FDA, 2016). As biosimilar research 
development reaches its seventh year within the U.S., four biosimilar agents have received FDA approval. 
Comparatively, following the first two biosimilar therapies approved by the EMA in 2006, over 20 
biosimilar products are approved for use within the EU (IMS Institute for Healthcare Informatics, 2016).   
Projections regarding the clinical and economic impact of biosimilar products have been met with 
controversy regarding biosimilar drug safety, provider perceived differences in drug efficacy, and 
complications within reimbursement and coverage within a privatized, for-profit, health care system.  
Additionally, U.S. patent litigation and disputes associated with the regulatory processes (e.g. naming 
convention, product interchangeability studies, unmet scheduled guidance meetings with the FDA and 
manufacturers) continue to stall successful implementation and access to biosimilar products.   
The purpose of this paper is to provide perspective and an objective assessment of key policy issues facing 
key health care stakeholders in the U.S. concerning drug safety and efficacy, drug cost and reimbursement 
policies set by payers, and the statutory regulation of interchangeability and substitution designation (of 
biosimilars with already approved reference biologic products).  Additionally, gaps in both patient and 
prescriber education in understanding the potential benefit of competitive biosimilar products present 
barriers to utilization as heeded by European healthcare analysts.  
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“Since their first introduction in the EU, biosimilar medicines increased patient access by 44% in the EU-5 
countries between 2006 and 2014.” –Carol Lynch, Global Health of Biopharmaceuticals at Sandoz and 
Chair of the Biosimilars Medicines Group (Medicines for Europe, 2016) 
As U.S. utilization of biosimilars is assessed, we may glean insight from the EU comparative biosimilar 
market initiated in 2005 regarding best practices, barriers to biosimilar utilization, and overall patient (and 
population) health improvements associated with increased access to effective and costly biologic 
medicines.  
2 BACKGROUND 
 
Biosimilar products are a class of biologic products that are high similar to a previously approved Food 
and Drug Administration (FDA) product, called a reference or originator product for purposes of this 
review.  Conceptually, biosimilar products were anticipated to reduce health care costs associated with 
the most expensive drug class, the biologic products.  The lower cost of biosimilars compared to reference 
biologic therapies were anticipated to increase utilization and access for patients requiring costly 
therapies for chronic and debilitating disease.   
The current U.S. biosimilar market will increase competition directly with biologic reference products 
following the expiration of patent exclusivity. The primary focus of this paper will include a review of 
rheumatology and diabetes biosimilar products due to imminent patent expirations (IMS Institute for 
Healthcare Informatics, 2016, p.4).  As the apporoval of biosimilar products commonly overlap  within the 
EU and U.S., comparisons for both systems are relevent and included within this paper.  A recent cost 
savings projection associated with U.S. biosimilar utilization by the CBO estimates that the competition 
from biosimilars would reduce drug spending to about $25 billion over ten years, saving the federal 
government nearly $6 billion.  Moving forward, key determinants of the successful implementation and 
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benefit of biosimilars will rely on several key factors including: federal and state statutory regulation of 
biosimilar access (i.e. interchangeability designation and substitution with reference biologic products) 
state-by-state), manufacture pricing, reimbursement and insurance formulary positioning and 
incentivisation, and acceptance of safety and efficacy by prescriber and patient shareholders (Robert 
Wood Johnson Foundation, 2013). 
2.1 EMA Biosimilar Regulatory Pathway 
 
The European Medicines Agency (EMA) approved the first biosimilar for availability within the EU in 2006, 
through the approval review process regulated by the EMA’s Committee for Medicinal Products for 
Human Use (CHMP) (Morton, 2017).  EMA successes in the biosimilar market include achieving greater 
drug access and cost savings. Currently, 20 biosimilars are approved within the EU (Kucher, 2016). 
As the cost of biologics is a considerable accessibility barrier for patients globally, the biosimilar 
competitive market in the EU provides alternative biologic products at approximately 25-30% lower cost 
than the reference biologic medicine. The EMA defines a biosimilar medicine as follows: 
A similar biological or “biosimilar” medicine that is similar to another biological medicine that has 
already been authorized for use. Biological medicines are medicines that are made by or derived 
from a biological source, such as a bacterium or yeast. They can consist of relatively small 
molecules such as human insulin or erythropoietin, or complex molecules such as monoclonal 
antibodies  (EMA, 2017). 
The EMA established an expedited approval pathway based on aspects of the previously approved 
(reference biologic) scientific development program.  More specific to biosimilar review, demonstration 
of bioequivalence with a reference medicine is required.  Biosimilar comparability, or the evaluation of 
manufacturing processes, chemical characterization of the biosimilar compound including 
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source/posology, route of administration, and deviation from reference product strength, formulation, 
excipients, are noted and may require additional review.   
Importantly, interchangeability designation of biosimilars is not determined by the EMA drug application 
process.  Interchangeability status by EMA, “ … are within the remit of the EU member states.” ((EMA), 
European Medicines Agency, 2014) . In consideration of  product exclusivity for biologics marketed in 
the EU, the EMA defines a period of marketing exclusivity as the “ 8 + 2 year rule” .  During the first 8 
years  from market authorization, no generic product manufacturer can submit reference biologic data 
for regulatory review.  After a period of 10 years, a generic product manufacturer can submit the 
reference product data for market authorization (TaylorWessing, 2015). 
Finally, drug manufacturers submit a single drug application for biosimilar approval for all EU member 
states to minimize redundancy and reduce application costs (EMA, 2017). 
2.2 US FDA/CDER Biosimilar Regulatory Pathways 
 
The U.S. biosimilar market has been less successful in terms of accessibility compared to the EU, largely 
due to health care policy reform and legislation effectively preserving biologic reference product viability. 
As part of the Patient Protection and Affordable Care Act (PPACA), new biologic products are now eligible 
for 12 years of market exclusivity, as codified in the Biologics and Price Competition and Innovation Act 
(BPCI).  The BPCI Act  also designated an abbreviated approval pathway for biosimilar approval, as part of 
an amendment to the Public Health Service (PHS) Act Section 351(a). The biosimilar approval pathway and 
the aforementioned biologic exclusivity regulation are defined within Section 351(k) and Section 
351(k)(7)(C) of the PHS Act respectively (PHS Act, 2009).   
 To evaluate biosimilarity, the 351(k) pathway diverges from traditional drug development clinical trials 
(as defined in Section 351(a) of the PHS Act).  FDA uses a “totality-of-the-evidence” approach in which 
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there is not one pivotal study or human participant clinical trial that demonstrates “effectiveness”. Instead, 
analytical studies, animal studies, and a clinical study (or studies) on the most sensitive indication, as 
determined by the manufacturer in conjunction with the FDA, are components of a biosimilar 
development program.  
FDA has four biosimilar classifications of based on analytical characterization: not similar, similar, highly 
similar, and highly similar with fingerprint-like similarity.  If a biosimilar compound is deemed as not similar, 
the drug application has no formal guidance. However, the cost associated with an investment (sponsor) 
would likely not continue through the 351(k) regulatory pathway.  Next, a similar designation requires the 
sponsor must present additional information/evidence to determine if the product is highly similar to the 
reference product. The third classification, highly similar, meets the analytical standard for analytic 
similarity and would continue through the 351(k) pathway to determine selective/specific demonstrated 
biosimilarity. Finally, highly similar with fingerprint-like similarity classification is defined “…based on 
integrated, multiparameter approaches that are extremely sensitive in identifying analytical differences.” 
(FDA, 2016, p. 15)  The assessment of interchangeability would be assessed in highly similar classifications 
of biosimilars if the sponsor submitted additional switching studies.  Switching studies, or crossover design 
studies, are direct comparative assessments in efficacy and immunogenicity to simulate and determine 
effects of switching in real life from the reference product. Therefore the patient or participant should 
represent the final user (e.g. patient with RA).  Additionally, switch over study design requires direct 
comparison of the biosimilar with the proposed U.S. reference product, not an alternative treatment or 
placebo (FDA, 2016). 
As previously described, the 351(k) biosimilar pathway was created to provide an abbreviated FDA review 
focused on the analytical structure and function of a molecule.  The program structure of the biosimilar 
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351(k) program is depicted in figure 1, including a side-by- side cartoon of the traditional 351(a) program 
and the 351(k) program. 
Figure 1: U.S. Biosimilar 351(k) and Biologic 351(a)  Program Comparison 
 
 
 
 
Through the totality of evidence, a biosimilar product development program must demonstrate little to 
no clinically meaningful differences in terms of safety and efficacy through chemical analysis and 
standardization of manufacturing that are similar to a US licensed reference product.  
The introduction of the abbreviated biosimilar pathway was anticipated to expand access to biologic 
medications through providing alternative and more affordable options, generic biosimilars, thereby 
creating a more competitive biologic market.   
Additional Clinical 
and 
Immunogenicity 
Studies
Comparative Human 
Pharmacology Studies 
(pharmacokinetics and 
pharmacodynamics)
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Biosimilar Development Program 
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As of March 2017, four biosimilar products have been granted approval since enactment of the PPACA in 
2010.  Key potential barriers identified for biosimilar manufacturers depicted in figure 2 include regulatory 
burden, statutory burden, and collective market risks that impact the U.S. biosimilar industry (Matrix 
Global Advisors, 2015, p.1).  Moreover, the Centers for Medicare & Medicaid Services (CMS) regulation 
practices of restriction of cost, fixed cost, and complex reimbursement practices also reduce the long-
term success of a functional competitive market. (IMS Institute for Healthcare Informatics, 2016). The 
onset of multiple citizen petitions by stakeholders, patent infringement litigation, and interchangeability 
concerns have added to the instability of the biosimilar market and implementation of alternative lower 
cost medicine therapy.  
In summary, the ongoing biosimilar market sustainability within the U.S. relies on the balance of health 
care policy legislature to ensure safe and effective biosimilar drug utilization, incentives for biosimilar drug 
development and education for increased prescriber stakeholder buy-in, requiring incentives for physician 
regulated standard practices.  
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Figure 2: Barriers to the proposed US Biosimilar Public Health Impact Pyramid 
 
3 Methodology 
 
Searches of federal, state, and stakeholder data repositories were conducted to assess an overview of 
biosimilar policy development within the U.S. during the period of 1/2013-12/2016 (Table 1).  The 
background literature search was explored by both topic-specific database and integrated search 
methodology. Federal data repository literature searches pertaining to implementation of the biosimilar 
legislation was obtained through assessing FDA organizational chart resources leading to the identification 
of FDA Center for Drug Evaluation Research (CDER) and the Center for Biologics Evaluation Research 
(CBER).  Through CBER resources, the Biologic License Applications (BLA) and Biosimilar User Fee Act 
(BsUFA I) as the U.S. biologic approval pathway was identified.   
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Table 1:   Online Literature Search Methodology  
 
Federal State EU-
7/Global 
Legal Medical/Misc. 
DHHS, FDA, CBER, 
CDER regulations.gov 
NCBOP EMA, 
WHO 
NCLS.org PUBMED, NCBI, ACA, Kff.org, ASHP, AMA, 
NIH, Google scholar, purple book, Pew 
Chart Trusts 
Summary of biosimilar resources and databases: U.S. Department of Health and Human Services (DHHS), Center for Medicare and Medicaid 
Services (CMS), The Food and Drug Administration (FDA), Center for Biologics Evaluation and Research Organization CBER, Center for Drug 
Evaluation and Research (CDER), North Carolina Board of Pharmacy (NCBOP), European Medical Association (EMA), World Health Organization 
(WHO), National Institute of Health (NIH), PUBMED, National Center for Biologic Institution (NCBI), The Alternative Care Act of 2010 (ACA), 
American Medical Association(AMA)  
Additional resources were identified through searching medical data using key word searches relevant to 
medical policy statements included in the analysis (Table 2). Other medical society literature review 
included: The American College of Rheumatology (ACR), Generic Pharmaceutical Association (GPhA), 
Biotechnology Industry Organization (BIO), and HSRA. 
Table 2:  Concept Search by Term  
 
Biosimilar Legislation  Biosimilar  Biosimilar Regulation Search  
Biosimilar AND 
ACA 2010, BCPI, FDA, 
CDER, CBER, EMA, 
CFR, State Regulation, 
approval, health care, 
stakeholder, safety, 
definition, CMS, 
manufacturer*, 
administration, Bill, 
committee, 
expansion, 351(k), 
policy, BsUFA, 
guidance, BLA, BsUFA 
Biosimilar 
market AND  
GPO, PBM, 
regulation, EMA, 
EU-5, EU-7, 
advantage* 
increase 
access*, 
outcomes, 
health care, 
integration, 
implement*, 
cover*, policy 
Biosimilar regulation 
AND FDA purple book, 
state law, policy,  
pharmacist, 
interchangeability, 
biologic substitution, 
manufacture*, lawsuit, 
patent, timeline, 
deductible, guidance 
Biosimilar AND diabetes, 
immunology, rheumatology, 
industry, pharma*, education, 
physician, patient, chronic 
disease treat*, improve* 
outcomes, stakeholders, 
timeline, recommendations, 
replacement, competition, 
limitations, concerns, 
comparison, afford*, quality, 
administration, choices, 
patient access, alternatives, 
cost, savings, rebate, white 
paper, guideline* 
Wildcard * 
Boolean term: AND 
Wildcard* 
Boolean term: 
AND 
Wildcard* 
Boolean term: AND 
Wildcard*  
Multiple tenses 
Boolean term: AND 
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4 Findings  
 
4.1 EMA Biosimilar Implementation  
 
The EMA has recently celebrated 20 years of existence (1995-2015).  The successful evolution of biosimilar 
products is considered a major milestone in scientific progress and development of new medicines (EMA, 
2017).  
EMA credits successful biosimilar market balance through fostering innovation while reducing costs 
associated with biologic therapy utilization.  Notably, the EMA approached biosimilar development by 
forming a working group, Biosimilar Medicinal Products Working Party (BMWP) to generate regulatory 
guidelines in 2005.  The BMWP underwent a consultative process to gain insight from key health care 
stakeholders to position guidelines as balanced in terms of regulatory demands and feasibility to research 
manufacturers.  Because the guidance provided by the BMWP included key stakeholder consultation, the 
EMA regulatory pathways reflect considerations for both safety and feasibility for biosimilar development 
programs. As the biosimilar market continues to grow within the EU-7 through EMA regulation, over 20 
products have been introduced (Table 3).  
4.1.1 EMA post-approval safety surveillance   
 
The EMA implemented a pharmacoepidemiology research process following biosimilar approval to track 
ongoing quality assurance and patient safety associated with biosimilar drug utilization.  Post approval 
safety surveillance and observational research are supported through the European Network of 
Pharmacoepidemiology and Pharmacovigilance Centers (ENCePP) in collaboration with the EMA.  Through 
the collaborative research initiative, over 100 research centers in Europe are integrated to perform 
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standardized and transparent post-approval research.  Funding for the research is facilitated by the EMA 
through its Pharmacovigilance Working Party/Pharmacovigilance Risk Assessment Committee (PRAC) and 
the Committee for Medicinal Products for Human Use (CHMP).  Essentially, the span of funding medicine 
safety/pharmacovigilance research includes the pharmaceutical industry, national public resources, and 
the European Commission stakeholder resources.  Further, health care practitioners are recognized as 
important participants in pharmacovigilance and safety assurance related to supervision and adherence 
to medicines.  The Working Party with Healthcare Professionals Organisations (HCPWP) promotes 
feedback and dialogue within the medicinal development partnerships.  Finally, at the public and patient 
level, drug safety transparency is available to patients through the European Public Assessment Report 
(EPAR), based on EMA scientific committee minutes (EMA, 2017).   
Patients have the right to know on which data and grounds a medicine is prescribed to them, 
and physicians and pharmacists should have the ability to know on which basis a medicine is 
granted access to the market. Therefore, we are broadening transparency on scientific data on 
which regulatory decisions are based. (EMA, 2017, p. 64) 
 
4.2 U.S. Biosimilar Implementation  
 
Comparatively, both federal and state statutory authorities regulate biosimilar drug substitution and drug 
interchangeability separately.  As previously described, the Patient Protection and Affordable Care Acts 
were enacted with a specialized drug application pathway, The Biologics Price Competition Act (BPCI) Act 
of 2009, to modify section 351 (42 U.S.C. 262) of the Public Health Service (PHS) Act  (FDA CDER, 2016) .  
All biosimilar biological product applications are reviewed under a new pathway designated the Biosimilar 
User Fee Act (BsUFA), incorporated as part of section 351(k) of the PHS Act (FDA, 2016).  A distinct 
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difference between U.S. and EU biosimilar drug statutory framework includes the designation of biosimilar 
interchangeability.   
Within the U.S., interchangeability status is assessed if the biosimilar sponsor requests interchangeability 
status designation as part of the submission proposal.   FDA guidance for biosimilar interchangeability 
includes studies to assess comparative efficacy and demonstration of no clinically meaningful differences 
between the biosimilar and the U.S. reference biologic drug.   To attain interchangeability status, 
extrapolation of interchangeability must be demonstrated with the specific U.S. biologic reference 
product as EU comparator biologics are not acceptable. Additionally, cross-over (switching) studies, 
designed to mimic real world use pertinent to efficacy and adherence are required.  Of the four current 
biosimilar products approved by FDA (table 3), none have interchangeability designation.   
Table 3 U.S. Approved Biosimilars (CDER, 2016) 
 
Biosimilar Reference Product Date of approval Interchangeability 
Filgrastim-sndz (Zarxio) Filgrastim (Neupogen) 3/6/2015 no 
Infliximab-dyyb (Inflectra) Infliximab (Remicade) 4/5/2016 no 
Etanercept-szzs (Erelzi) Etanercept (Embrel) 8/30/2016 no 
Adalimumab-atto (Amjevita) Adalimumab (Humira) 9/23/2016 no 
 
Despite early challenges within FDA, including government shutdown policy impact, enrollment in the 
Biosimilar Product Development Program (BPDP) has grown from FY2013 from 33 BLAs to 66 BLAs in 
FY2016 (Matrix Global Advisors, 2015). FDA remains undecided on key elements for biosimilar regulation 
and guidance updates, including mandated biosimilar nomenclature or naming requirements, post-
marketing surveillance requirements, and review for interchangeability.   
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4.2.1 Summary of State Law and legislation related to Biologic Medications and Substitution 
of Biosimilars, 2013 through 2016  
 
During the past six years, 36 states have established state standards for interchangeability (substitution) 
of a biosimilar to replace a reference biologic (Cauchi, 2016). Common features of state regulations 
provide the authority for prescribers to substitute biosimilars if approved as “interchangeable” by the FDA. 
Additionally, individual patients must be notified that a substitution has been made, and the pharmacist 
is allowed to substitute biologics with biosimilars. Laws enacted in Colorado, Georgia, Illinois, North 
Carolina, and Texas requires that an authorized or allowable substitution must be the lowest cost or price.  
 In North Carolina, Bill H 195 was proposed by (R) Dollar and signed on 05/21/2015. The law “amends the 
Pharmacy Practice Act to allow for the substitution of an interchangeable biological product.” Additionally, 
the NC pharmacist must “communicate” not “notify” a prescriber.  This requirement allows the 
pharmacist to enter into an electronic health record but not notify the prescriber directly.  Finally, the NC 
Board of Pharmacy must post a list of interchangeable products for pharmacists to choose (Cauchi, 2016).  
The Pew Charitable Trusts Organization states one study found that requiring patient consent reduces the 
rate of generic substitution by 25 percent (Trusts, 2017).  Although FDA interchangeability status has not 
been granted for any biosimilars in the U.S., the ongoing concern regarding state regulatory policy effects 
on biosimilar utilization should be warranted.  
 
 
4.3 EU and US Industry Biosimilar Patent Litigation  
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Within Europe and the U.S. patent infringement and patent litigation processes impact the availability and 
thus utilization of biosimilar products. The most common strategy to challenge a reference drug patent 
within Europe is through the European Patent Office (EPO).  Use of the EPO is due to the lack of a single 
court to rule on all filings, now more contentious since UK Brexit.  Notably, this strategy allows for a single 
EU patent regulation on a European Unitary Patent (EUP).   The purpose of unification is to stimulate drug 
innovation and associated costs of development.  
 U.S., industry stakeholders have recently impacted the U.S. biosimilar market with legal patent dance and 
litigation holding on biosimilar accessibility. The patent dance, described as patent litigation provisions 
associated with the new biosimilar pathway, has two phases.  Within phase I, the registered biologic 
patent holder (for reference biologic) must bring suit against the biosimilar applicant with respect to the 
patents included in the supplied patent list (to the biologic patent holder) within 30 days.   Phase 2 occurs 
just prior to biosimilar launch, as the biosimilar sponsor must provide 180-day notice before commercial 
launch.  During the 180 day window, the reference biologic patent holder can seek a declaratory judgment 
(Malkin, 2015).   
 
4.4 Payer Landscape Influence of Biosimilar Utilization 
 
Commercial payers, large employer groups, managed Medicaid programs, and Part D programs often 
contract with PBMs to manage prescription drug benefits. The payer may outsource all aspects of 
pharmacy benefit management to the PBM or opt for select services, such as developing and 
administering utilization management programs. Some common designs in plan benefit administration 
that payers and PBMs use to manage drug utilization are described in table 4.  
Table 4: Common drug utilization management tactics used by Payers 
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Prior Authorization: Approval from a payer prior to reimbursement of medication 
Step-edits:  A graduated treatment protocol directing to physicians the order in which the must 
administer different therapies for a given condition 
Quantity/Duration Limit: Limits the amount of a drug that may be dispensed at one time and or the 
duration of use  
 
4.4.1 Buy and Bill Practices 
 
Physician practices typically acquire biologics administered to patients within their office from wholesale 
distributors in a process referred to as “buy and bill.”  Medical practices and clinic purchases providing 
“buy and bill” services will purchase the drug, manage the inventory, administer the drug to a patient, and 
bill the patient’s insurance provider for the product and the medical services provided. Medical practices 
and large Institutional Delivery Networks (IDNs) will often join a group purchasing organization (GPO) in 
order to receive price discounts.  Commercial payers reimburse physicians for drugs that are administered 
in the office using the manufacturer average sales price (ASP) formula, as instituted by the Center for 
Medicaid and Medicare Services (CMS).  The practice also receives a small markup on the price to 
compensate for storage, handling, infusion, and other administrative costs.  For comparison, patients with 
Medicare coverage generally provide a structured reimbursement to physician practices and clinics at ASP 
+ 6 % (IMS Institute for Healthcare Informatics, 2016).   
Biopharmaceutical manufacturers are required to calculate an ASP every quarter and submit that 
information to CMS within 30 days of the close of each quarter. CMS updates their ASP reimbursement 
rates for Medicare Part B drugs on a quarterly basis.  This process means that the price of a drug can 
fluctuate from quarter to quarter, which influences the amount the physician is reimbursed.  Medical has 
recently proposed changing the reimbursement for Medicare Part B drugs from ASP + 6% to 2.5% ASP plus 
a flat fee payment of $16.80 per drug per day (FDA, 2016).  
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Medicare Part B and Part D payment programs are currently both utilized by physicians and health care 
organizations to obtain reimbursement for biologics and biosimilars.  Medicare Part B includes provider-
administered drugs regardless of inpatient or outpatient status.  Medicare Part B will reimburse providers 
at 106% of the Wholesale Acquisition Cost (WAC) for the product until ASP information is available after 
two full quarters of sales data have been reported to CMS.  Once the ASP is established, drug 
reimbursement reverts to ASP + 6%.  Medicare Part D, voluntary plans vary related to formulary and cost-
sharing structure.  The types of utilization management tools also vary by plan.  As part of standard 
benefits, the cost of biosimilars under Part D plans shift the cost share to patient responsibility through 
co-payment and/or donut hole status related patient cost payment structure.   
Drug coverage under a Pharmacy benefit (buy and bill versus contracted specialty pharmacy) is 
determined by coding, although traditionally fewer utilization controls are associated with the medical 
benefit.  Importantly, drug utilization under the pharmacy benefit has higher out of pocket patient cost, 
through co-pay or coinsurance.  Drugs covered under the pharmacy benefit are typical subject to several 
utilization controls to ensure appropriate use, such as copayment tiers, prior authorization, and step edits.  
As health plans incur rising costs due to specialty drugs, they are shifting the coverage from the medical 
benefit to the pharmacy benefit.  As a consequence, this means that patients may pay higher out of pocket 
costs for these specialty (biologic) drugs.  
 
 
4.5 U.S. Prescriber Perception of Biosimilars  
 
Key findings pertaining to U.S. prescriber perception of biosimilars include a summary of the 2015 
American Committee of Rheumatology (ACR) Position Statement to FDA, the European National 
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Rheumatoid Arthritis Society (NRAS) Position Paper on Biosimilars, and relevant key findings from a GaBI 
Survey published in 2015.  
4.5.1 Overview of the ACR Position Statement 
 
 The ACR medical society attests that from a purely analytic characterization and thus functional aspect 
of biosimilar development programs, biosimilar manufacturers that sponsor and develop biosimilars do 
not have access to proprietary manufacturing processes.  Because analytic characterization of the highly 
specialized isoforms of biologics is closely tied with therapeutic benefit and efficacy, slight product 
variation in biosimilar compounds respective of originator biologic reference compounds that are highly 
complex is not out of the question depending on the sensitivity/specificity of FDA program review 
pertaining to chemical characterization analytic evidence. Pointedly, the ACR described the historical 
safety concerns associated with utilization of the biosimilar product of the reference biologic 
erythropoietin (EPO).  The emphasis highlighted the need for more stringent approval processes and 
regulation in the U.S. as the utilization of the biosimilar was associated with serious adverse events 
following 1998 biosimilar approval by the EMA.  The most alarming drug adverse events included a life-
threatening adverse event was associated with the EPO “similar” product, Eprex, approved in the EU but 
not in the US.  A minor change in Eprex manufacturing led to a 95 % increase in the number of cases of 
pure red cell aplasia (PRCA).  More recently, another increase in reported PRCA in Thailand was associated 
with other biosimilar EPO medicines. The ACR recommends that only treating physicians should be 
allowed to substitute a biosimilar for a reference biologic or the switch among biosimilar medicines due 
to such safety concerns. A summary of the key policy concerns are listed in table 5 below from the ACR in 
response to the August 2015 FDA issued draft guidance for biosimilar policy (ACR , 2015):  
Table 5: ACR Summary Response to FDA Draft Guidance for Biosimilar Policy (ACR , 2015, p. 5) 
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The size, complexity, and heterogeneity of biologics (and biosimilars) require greater scientific evidence 
and analytical evaluation than generic small molecule drugs passed through the U.S.C. 355(j) Drug Price 
Competition and Patent Term Restoration Act (Hatch-Waxman Act of 1984) 
 
Clinical trials in humans are necessary to ensure the safety and efficacy of biosimilars 
 
The decision to substitute a biosimilar product should only be made by the prescribing provider 
 
Providers must retain the right to write “dispense as written” or “brand medically necessary” for all 
prescriptions 
 
Biosimilars have to have distinct names to ensure accurate pharmacovigilance 
 
Long term post-marketing registry based data collection for each biosimilar is necessary to monitor for less 
common but important adverse events  
 
The ACR objects to compulsory switching of stable patients to a different medicine including biosimilars for 
cost saving reasons without consent from the prescribing provider 
 
 
4.5.2 Overview of NRAS Position 
 
 NRAS posits that at the time of the position paper revision (March 2016), only two biologic products, 
Remicade/infliximab and Enbrel/infliximab had biosimilar approved alternatives available in the UK for 
the treatment of Rheumatoid Arthritis.  Overall, the biosimilars demonstrated, “…similar therapeutic 
efficacy and incidence of drug-related events, are well tolerated, and have a comparable record of safety.” 
(NRAS, 2016, p. 2) 
Key concerns regarding ongoing utilization of biosimilars for highly complex treatment include 
pharmacovigilance efforts, cost, and increased access to patients.  Due to reduced drug cost to the health 
care system, utilization of the biosimilar products to treat Rheumatoid Arthritis (RA) is encouraged.  The 
concern, extrapolation of the abbreviated analytics based drug development pathway to treat all patients 
with RA, is noted.  Further, patient eligibility criteria for use (e.g. guideline aligned practice) lags behind 
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the wider access availability associated with biosimilar utilization.  Notably, NICE declined the BSR/NRAS 
appeal to widen access to patients with moderate to severe disease with poor prognostic disease 
indicators.   Comparative NRAS and ACR policy position recommendations are included in table 6 below, 
focused on healthcare professional, patient, industry, and health care entity stakeholders.   
Table 6: Comparison of NRAS and ACR Biosimilar Policy Position 
 
Stakeholder Key Statement recommendations Comparative Statement within U.S. ACR 
HCP  -Substitution (i.e. switching) should 
occur under HCP supervision w/patient 
consent 
 
-Health care professionals should prescribe 
biologics/biosimilars by brand name and NOT 
international non-propriety names (e.g. generic 
name) 
People  
with RA 
-people w/RA should be fully aware of 
which medications are switched to 
biosimilars 
-people should be made aware of 
pathways/process for complaints  
- no patient level recommendations for ACR 
statement 
Industry  -All data should be publically available 
-nomenclature (naming) should have 
distinct names 
- should support finances for training 
HCPs, education for patients 
- responsible for the collection of 
longitudinal safety data 
- nomenclature (naming) should be unique and 
include the biologic (reference) product on labeling  
Healthcare 
bodies 
-British Society for Rheumatology 
Biologics Register captures essential 
outcome data 
-NICE updates guidance on use of 
biosimilars (include) 
-no recommendations for FDA 
 
Additionally, NRAS revealed that although biosimilar availability has improved patient access due to 
decreased medication cost, the access is not consistent outside of mainland Europe due to more stringent 
accessibility regulation.  Until NICE revises guidance to include specific biosimilar utilization (update), 
increased access will be limited geographically (NRAS, 2016).   
4.5.3 Overview of The GaBI Survey analysis  
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The Generics and Biosimilars Initiative Journal (GaBI Journal) assessed barriers to biosimilar uptake within 
the U.S. in 2014.  Overall, the objective of the survey analysis provided data on two healthcare market 
stakeholders, physicians, and payers.  Overall results report 70% of prescribers responded they are likely 
to prescribe a biosimilar to treatment-naïve patients. Regarding switching an existing patient to a 
biosimilar from the reference biologic, 8%, 61%, and 31% responded very likely, somewhat likely, and not 
likely respectively.  For payers, 7 of 8 respondents reported they were very likely to include biosimilars on 
formulary.  Further, the inclusion of biosimilars would be tiered to differentiate between the biosimilar 
and biologic.  75% of payer respondents expect biosimilars to have a 15-35% price discount as compared 
to the biologic reference product (GaBI, 2014).   
4.5.4 Relevant Outcomes from Danbio Danish Registry 
 
Outcomes from the Danbio Danish Registry presented at the ACR 2016 Annual Meeting reported results 
of 768 patients with inflammatory rheumatic disease treated with Remicade for greater than four years.  
These patients did not experience disease progression after the non-medical switch to the biosimilar 
Remsima from the Biologic reference product, Remicade (during three months prior and three months 
post switch monitoring). Other important findings reported 15% (117) of patients discontinued treatment, 
34 due to adverse effects, and 51 due to lack of effect. Study authors recommend further investigation as 
to patient specific adherence and barriers to therapy use during switching periods between the biosimilar 
and biologic reference product use (Glintborg B, 2017). 
5 Discussion 
 
The European biosimilar market leads the way regarding approvals, increased patient access, and overall 
regulatory implementation (by the EMA). The near-term health care cost savings opportunities for 
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biosimilars in two therapeutic areas in the U.S., Inflammation (Rheumatology) and Diabetes rely on 
multiple stakeholders.  The savings opportunity provided by the biosimilars is timely, considering ongoing 
budgetary constraints within the current political landscape.  Biosimilars also provide an avenue to 
support the patient goal, to improve their health outcomes and quality of life.  Thus, increased access to 
biologic therapies represents an important policy goal.  Disincentives for biosimilar use include payer price 
fixing (e.g. ASP calculated cost), physician resistance to adoption, increased development cost and 
litigation within the pharmaceutical industry, and lack of consistent interchangeability within each state.   
In June 2015, AbbVie Inc., the manufacturer of the biologic Humira (adalimumab ) filed a citizen petition 
questioning the FDAs approach to biosimilar labeling related to the biosimilar Amjevita (adalimumab-atto). 
Highlights of AbbVie’s petition include advocating that approved prescription drug labeling for biosimilar 
products licensed under section 351(k) of the PHSA contain (FDA, 2015):  
 A clear statement that the product is a biosimilar, that the biosimilar is licensed for fewer than all 
the US-licensed reference products conditions (if applicable) (AbbVie Inc., 2015) 
 A clear statement that the FDA has not determined that the biosimilar product is interchangeable 
(if applicable) (AbbVie Inc., 2015) 
 A concise description of pertinent data developed to support licensure of the biosimilar, along 
with information adequate to enable prescribers to distinguish data derived from studies of the 
US –licensed product (AbbVie Inc., 2015)    
In response, FDA currently aligned with only the requirement, that the drug label includes a clear 
statement that the product is a biosimilar.  The naming convention guidance for biosimilars now includes 
a 4-letter suffix “devoid of meaning” as part of the name of all biologic products, including US-licensed 
reference products and biosimilar products (Goodwin, 2017).   
The FDA also asks for public comment on an alternative option in which the suffix would not be 
meaningless but instead be derived from the name of the license holder. The proposal also states that the 
4-letter suffix will be different for each product, except perhaps interchangeable products.  Public 
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comment notification processes, public meetings, and live discussion forums were held to discuss 
modifications needed within The Biosimilar User Fee Act (BsUFA) set to expire in December of 2017.  A 
Public Meeting Agenda for public comment was held on October 20th, 2016 that included a forum for key 
stakeholders to submit and voice comments and recommendations for the reauthorization of the expiring 
BsUFA for fiscal years (FYs) 2018 – 2022 (Goodwin Proctor LLP, 2016).  
FDA final recommendations for reauthorization of BsUFA through implementation of BsUFA II, all public 
comments are to be submitted to the U.S. Congress for review no later than January 15th, 2017.  Clearly, 
many stakeholders influence the balance of a viable Biosimilar Market that BsUFA II regulates and FDA 
holds the responsibility to effectively and completely execute a drug application review processes as set 
through the BsUFA regulatory mandates.  Ultimately, however, the final responsibility to assure the safe 
biosimilar drug utilization falls on U.S. prescribers as they monitor and regulate patient treatment and 
adherence (CDER, 2016). 
5.1 Lack of Biosimilar Interchangeability Approval  
 
U.S. approved biosimilars provide options to drug developers to pursue biosimilar approval designation 
alone or as a biosimilar with interchangeability. While the FDA has not established standardized regulatory 
criteria that are necessary to determine the criteria for interchangeable designation for biosimilars, 
guidelines for study design to support interchangeability are provided.  U.S. healthcare payers must 
balance the goals of ensuring that customers have appropriate access to the clinical benefits of available 
medications with the need to manage the costs of medications and overall expenditures within budget.  
This payer balance has become especially challenging with the introduction of biologics and that have the 
potential to improve clinical outcomes for many patients but continue to be prohibitively expensive.  
Moreover, the introduction of biosimilars in the U.S. healthcare system may provide more affordable 
options that are safe and effective through the competitive market.  Unfortunately, the challenge to 
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manage biologic medicine cost includes a paradigm shift in the perception on what definitively ensures 
safety and efficacy to important stakeholders, the prescribers and patients. Because FDA focused on 
analytics and PK/PD studies, the programs lack clinically significant information.  The Biosimilar 351(k) 
development methods focus on biosimilarity through analytical methodology in normal (healthy) 
volunteers, utilizing data extrapolation, rather than Phase 3 clinical trials.  
6 Recommendations 
 
6.1 Establish Stakeholder Driven Best Practices 
 
Prescriber stakeholder recommendations include improved education regarding biosimilar therapy, 
being able to consistently improve health care outcomes for patients through increased access to costly 
medications.  Additionally, prescribers in the U.S. have voiced concern regarding maintaining their 
freedom in prescribing biosimilar medications for the appropriate patient.   
Supportive physician education regarding the paradigm shift from 351a to k: change the focus and 
educational message to describe the value of demonstrated biosimilarity and patient population (e.g. 
new starts instead of generic interchange among patients with established biologic product treatment). 
Manufacturing and FDA have improved educational efforts regarding the 351(k) approval process, thus 
improving the inherent differences of biologic and biosimilar pathway review processes.  Simply 
providing CME educational resources to describe the analytical basis to the review processes (assessing 
critical physical, chemical, biological characteristics of a molecule) that truly define the similarity tied to 
structural and functional analysis is paramount to successful biosimilar product acceptance.  
Understanding the variability controls in manufacturing (i.e. specifications of testing, appropriate 
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acceptance criteria), potentially as part of labeling may also reduce questions regarding lot to lot 
variability or genetic drift concerns (US Food and Drug Administration, 2016).   
6.2 Make Better Use of Available Resources 
 
Resources for prescriber CME education include: FDA CDER educational programs, Medical Societies 
(e.g. American Medical Society), FDA resources online, purple book for biosimilars, pharmacists and 
health system pharmacy resources (i.e. American Society of Health System Pharmacy (ASHP)) Industry 
manufacturer websites, and GPO/Specialty pharmacy outreach programs (e.g. Express Scripts).  
ASHP recommendations also emphasize understanding the rationale regarding the biosimilar 351(k) 
pathway, predicated on the use of analytic scientific supportive evidence instead of clinical safety/efficacy 
trials.  Every stage of the analytics is focused on validating structural similarity (function is extrapolated 
from the structure of the compound/specificity).  Further, explaining that neutralization binding assays (% 
neutralization of primary target) and analytical studies are completed against the originator biologic to 
determine target binding comparative to reference biologics. The American Society of Health System 
Pharmacists provided the following educational recommendation, referred to as the ABCs and E of 
Biosimilar Provider Education summarized in Table 7: Table 7: ASHP “ABC and E’s of Biosimilars” (ProCE, 
Inc., 2016) 
 
Table 7: ABC and E’s of Biosimilars  
Accept the accuracy of analytics 
Build a bridge to understand clinical comparisons with non-U.S. licensed products 
Curb the expectation of safety and efficacy trials and embrace extrapolation data 
What is Extrapolation: define what it would mean for each compound but in general  
Extrapolation is based on the originator (reference) mechanism of action, 
Pharmacokinetic and bio distribution in different patient populations and 
immunogenicity and toxicology profiles in different disease states (for separate 
indications) 
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6.3 FDA Biosimilar Resource: The Purple Book 
 
The Purple Book is a primary resource for all biosimilar and biological products, including 
interchangeability designation, licensed by FDA (U.S. Dept. of Health and Human Services, 2017).  CMS 
recommends instructing physicians and pharmacists on how to prescribe and dispense cost-effective 
biosimilars to maximize use.  It is important to point out that a prescriber may have to write the 
proprietary name of the biosimilar product as found in the FDA Purple Book for it to be dispensed; a 
prescriber may not be able to simply write the proprietary name of a reference product and expect the 
pharmacist to substitute it with the biosimilar. The link for the Purple book and biosimilar list is included 
in appendices (appendix 1).    
7 Conclusion 
 
Considering the potential population health benefits associated with increasing patient access to biologic 
and biosimilar medications, the relevance of biosimilar medication within the public health sectors of 
policy and pharmacoepidemiology is keen.  Incorporation of the Friedman’s Health Impact Pyramid 
outlined in figure 2 depicts the statutory interventions and socioeconomic factors that provide the most 
benefit, improving the health care infrastructure and overall health of the population. Although 
educational interventions remain at the top of the pyramid, they remain critical to the successful 
understanding of biosimilar value within the U.S.  Having the ability to access costly medication truly falls 
on policy and statutory regulation of health care to align access to all individuals as part of the ACA goals. 
Consistent substitution policy to create less confusion and increase biosimilar access to the appropriate 
patients may be best regulated by physicians, medical societies, and FDA.  Payor stakeholders, if remit 
from policy impact due to profit motivation may difficult to remove.  As brand specific (non-generic) 
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incentives (e.g. rebate program structured cost reduction) are limited, the alternatives are limited to a 
reduction in price to offer similar value as the biosimilar product. 
  
  31 
 
Appendices:   
 
Appendix 1: Recommended Websites 
The Purple Book- list of licensed biological products with reference product exclusivity and Biosimilarity 
orInterchangeability 
Link: 
https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/A
pprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM412398.pdf 
 
National Conference of State Legislatures 
Link: 
http://www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-and-
substitution-of-biosimilars.aspx 
 
CME: FDA- CDER Overview of Biosimilar Products fdabiosimilars.e-paga.com/course/framework/index.html# 
 
CME: A Health-System Pharmacists Guide to Biosimilars: Regulatory, Scientific, and Practical Considerations  
Link:  
www.biosimcentral.org 
Reference Product Exclusivity Biological Products Filed Under Sect 351(a) of the PHS Act, August 2015 
Link:  
 http://www/fda.gov/downloads/Drugs/GuidanceComplanceRegulatorInformation/Guidances/UCM407844.pdf 
ClincalPharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product, May 2014 
Link: 
http://www.fda.gov/downloads/drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.pdf 
  
FDA Guidance for Industry, “QE5 Comparability of Biotechnological/Biological Products Subject to Changes in 
Their Manufacturing Process” 
Link: 
http://www.fda.gov/downloads/drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.pdf 
Formal Meetings between FDA and Biosimilar Biological Product Sponsors or Applicants, May 2013 
Link: 
http://www.fda.gov/downloads/drugs/guidanceComplianceRegulatoryInformation/guidances/UCM345649.pdf 
 
Quality Considerations in Demonstration of Biosimilarity to a Reference Protein Product, May 2012 
Link: 
 http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/  
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Appendix 2: EMA Approved Biosimilars (accessed March 1, 2017)  
 
Biosimilar 
 
Reference 
Biologic 
Therapeutic Area Authorization 
Date 
Manufacturer Post Marketing 
Abasaglar (previously 
Abasria) 
Insulin Glargine DM 9/2014 Eli Lilly and 
Boehringer  
Landmark approval: 1st 
biosimilar insulin 
Omnitrope Somatropin Turner Syndrome +2 
indications 
4/2006 Sandoz  
Valtropin Somatropin Turner syndrome +1 
indication  
4/2006 BioPartners w/drwn 5/2012 
Lusduna Insulin Glargine DM 1/2017 Merck  
Amgevita adalimumab RA +7 indications 1/2017 Amgen  
Benepali Etanercept RA+ 3 indications 1/2016 Samsung  
Flixabi Infliximab RA +5 indications 5/2016 Samsung  
Inflectra Infliximab RA +5 indications 9/2014 Hospira  
Remsima Infliximab RA +5 indications 9/2013 Celltrion  
Movymia Teripartide osteoporosis  1/2016 STADA  
Terrosa Teripartide osteoporosis 11/2016 Gedeon  
Solymbic Adalimumab RA + 6 indications 1/2017 Amgen  
Inhixa Enoxaparin 
sodium 
Venous 
thromboembolism 
9/2016 Techdow EU  
Thorinane Enoxaparin 
sodium 
Venous 
thromboembolism 
9/2016 Pharmathen  
Truxima Rituxumab RA +4 indications 12/2016 Celltrion  
Abseamed  Epoetin alpha CKD, Cancer, Anemia 8/2007 Medice 
Arzneimittel 
 
 
Binocrit Epoetin alpha CKD, Anemia 8/2007 Sandoz  
Epoetin alfa hexal Epoetin alpha CKD, Cancer, Anemia 8/2007 Hexal 
 
 
Retacrit Epoetin zeta CKD +3 indications 12/2007 Hospira  
Silapo Epoetin zeta CKD ++3 indications 12/2007 STADA   
Filgrastim Hexal Filgrastim Neutropenia +2 
indications 
2/2009 Hexal   
Accofil Filgrastim Neutropenia 9/2014 Accord 
Healthcare 
 
Filgrastim 
ratiopharm 
Filgrastim Neutropenia +2 
indications 
9/2008 Ratiopharm w/drawn 4/2011 
Biograstim Filgrastim Neutropenia + 2 
indications 
9/2008   
Grastofil Filgrastim Neutropenia 10/2013 Apotex  
Nivestim Filgrastim Neutropenia +2 
indications 
6/2010 Hospira  
Tevagrastim Filgrastim Neutropenia +2 9/2008 Teva Generics  
Zarzio Filgrastim Neutropenia +2 2/2009 Sandoz  
Bemfola Follitropin 
alpha 
Anovulation IVF 3/2014 Finox Biotech  
Ovaleap Follitropin 
alpha 
Anovulation IVF 9/2013 Teva Pharma  
Available online: http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe 
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